Synapse - Works

Results (137)

Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer

Meeting Abstract

Zhang, W.; Yang, D.; Capanu, M.; Hollywood, E.; Lue-Yat, M.; Borucka, E.; Azuma, M.; Gordon, M.; Saltz, L.; Lenz, H.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Phase I study of a novel capecitabine schedule based on Norton-Simon mathematical modeling

Meeting Abstract

Theodoulou, M.; Traina, T. A.; Dugan, U.; Lake, D.; Fornier, M.; Feigin, K.; Patil, S.; Edwards, C.; Norton, L.; Hudis, C. A.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

A phase II study of preoperative chemotherapy with irinotecan (CPT) and cisplatin (CIS) for gastric cancer (NCI 5917): FDG-PET/CT predicts patient outcome

Meeting Abstract

Shah, M. A.; Yeung, H.; Coit, D.; Trocola, R.; Ilson, D.; Randazzo, J.; Tang, L.; Brennan, M.; Divgi, C.; Kelsen, D. P.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Volumetric 3D CT analysis - an early predictor of response to therapy

Meeting Abstract

Schwartz, L. H.; Curran, S.; Trocola, R.; Randazzo, J.; Ilson, D.; Kelsen, D.; Shah, M.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Effect of percutaneous biliary drainage (PBD) for malignant biliary obstruction (MBO) on quality of life (QoL)

Meeting Abstract

Robson, P. M.; Heffernan, N.; Holmes, R.; Gonen, M.; Schubert, J.; Getrajdman, G. I.; Brody, L. A.; Brown, K. T.; Covey, A. M.; Blumgart, L. H.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Bevacizumab 5mg/kg can be safely infused over 10 minutes

Meeting Abstract

Reidy, D. L.; Chung, K. Y.; Timoney, J. P.; Park, V.; Hollywood, E.; Sklarin, N.; Muller, R.; Saltz, L.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991

Meeting Abstract

O'Dwyer, P. J.; LoRusso, P.; DeMichele, A.; Gupta, V.; Barbi, A.; Dials, H.; Chen, I.; Courtney, R.; Wilner, K.; Schwartz, G. K.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and IV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer

Meeting Abstract

Konner, J. A.; Fallon, K.; Pezzuli, S.; Iasonos, A.; Sabbatini, P.; Hensley, M.; Chiang, A.; Tew, W.; Spriggs, D.; Aghajanian, C.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

The implementation of a rapid response team at Memorial Sloan-Kettering Cancer Center: A preliminary report

Meeting Abstract

Klotz, A. D.; Thattassery, E.; Graham, D.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Phase I trial of PTK787/ZK222584 (PTK/ZK) in combination with carboplatin (C) and paclitaxel (T) in platinum-sensitive recurrent epithelial ovarian (EOC), fallopian tube (FT), or primary peritoneal (PPC) cancers

Meeting Abstract

Juretzka, M. M.; Aghajanian, C.; Hensley, M. L.; Tew, W. P.; Spriggs, D.; Konner, J.; Chiang, A. C.; Pezzulli, S.; Kim, M.; Sabbatini, P.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save